Recruitment unclearEUCTR 2017-000497-11

A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolarity type I Who are Early in Their Illness

This historical record does not confirm current site availability.

Historical research recordMultiple countries

The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Austria · Germany and 3 more locations
Study phase: Phase 3

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed

Recruitment status: Recruitment unclear
Enrollment listed in the registry: 425
Sponsor: Alkermes Inc
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Austria, Germany, Italy, ...
Age range: Not clearly listed
Official registry ID: EUCTR 2017-000497-11
Official title: Show the full official title
A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness

Get this study by email

Recruitment & locations

Status unknown

Austria · Germany · Italy

2 more locations

Romania
Spain

Registry details

Historical country statuses

Austria — Completed
Germany — Completed
Spain — Ongoing
Italy — Completed
Romania — Ongoing

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Alkermes Inc.

Want to explore more studies?

Explore studies